A Phase 2 interventional study of LY2157299 and Sorafenib in Carcinoma, Hepatocellular, sponsored by Eli Lilly and Company. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 3rd largest by enrollment, is the only one that started in 2011, is one of 4 in phase 2, and was the 5th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 47 across the 13 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
The study consists of four Parts: Part A where HCC participants with an increased alpha-fetoprotein (AFP) level will be treated with either 160 milligrams (mg) LY2157299 or 300 mg LY2157299. Part B where HCC participants with a normal AFP level will be treated with 300 mg LY2157299, Part C where treatment-naïve HCC participants will be treated with 160 mg LY2157299 + sorafenib or 300 mg LY2157299 + sorafenib, and Part D where HCC participants will be treated with either 160 mg or 300 mg LY2157299 + ramucirumab.
Participants who continue to receive benefit from treatment at the time that the study is considered completed, may enter the treatment extension period and continue to receive the study treatment. The end of the study is the date of last visit or last scheduled procedure for the last active subject in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have moderate or severe cardiac disease:
For Part D, have a serious illness or medical condition(s), including but not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299. 80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
Drug: LY2157299
150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
Drug: LY2157299 · Drug: Sorafenib
150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
Drug: LY2157299
80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
Drug: LY2157299 · Drug: Sorafenib
150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
Drug: LY2157299 · Drug: Sorafenib
80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
Drug: LY2157299 · Drug: Ramucirumab
150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle). Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
Drug: LY2157299 · Drug: Ramucirumab
Administered orally
Administered orally
Administered IV
Also known as: LY30098016
Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)
Biomarker response was defined as a \> 20% decrease in the biomarker AFP from baseline during 8 weeks of treatment. Data presented is median overall survival of those participants who achieved the defined biomarker response. Participants enrolled in Part A had a baseline AFP level of \>1.5 upper limit normal (ULN). Participants enrolled in Part B had baseline AFP level \<1.5 ULN.
Time frame: Baseline, discontinuation from any cause (Up to 83 months)
Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS)
Biomarker response was defined as a \> 20% decrease in the biomarker TGF-B from baseline. Data presented is median overall survival of those participants who achieved biomarker response.
Time frame: Baseline,discontinuation from any cause (Up to 83 months)
Time to Progression (TTP)
TTP is measured from the date of first dose to the first date of progression of disease based on the investigator review of tumor response using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
Time frame: Randomization to date of first measured progressive disease (Up to 36 Weeks)
Population Pharmacokinetics (PK) Mean Population Clearance of Galunisertib
Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.
Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1
Recommended Dose for Phase 3 Hepatocellular Carcinoma (HCC) Trials
Time frame: Cycle 1 (28 Days)
Overall Survival (OS)
OS duration is measured from the date of first dose to the date of death from any cause.
Time frame: Randomization to date of death from any cause (Up to 83 months)
Progression Free Survival (PFS)
PFS duration is measure from the date of first dose to the first date of objective progression of disease or death from any cause. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
Time frame: Randomization to measured progressive disease or death from any cause (Up to 45 Weeks)
Percentage of Participants Achieving an Objective Response (Response Rate)
The percentage of participants who achieved best overall response of either Complete Response (CR) or Partial Response (PR). The overall response rate for each dose with be estimated by dividing the number of confirmed responders by the number of participants who received at least one dose of study drug. Per RECIST v.1.0 criteria CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.
Time frame: Randomization to measured progressive disease (Up to 36 Weeks)
Duration of Tumor Response (DoR)
DoR is measured from the date of the first objective status assessment of a Complete Response (CR) or Partial Response (PR), as determined by RECIST v1.1, to the first date of objective progression of disease or death from any cause. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
Time frame: Time of response to measured progressive disease or death from any cause (Up to 84 Weeks)
Time to Treatment Failure (TTF)
TTF is measured from the date of first dose until the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause.
Time frame: Randomization to the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause (Up to 75 Weeks)
Change From Baseline in Functional Assessment of Cancer Therapy, Hepatobiliary (FACT-Hep) Sub-scores and Total Score
FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72; FACT-Hep score range 1-180, and Trial-Outcome Index (TOI) score range 1-128, to assess health related quality of life in participants with cancer. Higher scores reflect a better health state.
Time frame: Baseline, Day 1 Cycle 4
Time to Worsening (TTW) of Symptoms (FACT-Hep)
Time to worsening of symptoms used minimally important differences to evaluate Physical Well Being (PWB), Functional Well Being (FWB), Hepatocellular Cancer Symptoms (HCS), National Comprehensive Cancer Network (NCCN)/FACT Hepatocellular Symptoms (FHS), Trial-Outcome Index (TOI). PWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; FWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; HCS time to worsening was defined as participants who had change in a subscale of ≥ 5 point decrease from baseline; FHS time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; TOI time to Worsening was defined as participants who had change in the subscale of ≥ 7 point decrease from baseline.
Time frame: Baseline to the worsening of symptoms (up to 567 days)
| Milestone | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab |
|---|---|---|---|---|---|---|---|
| Started | 37 | 72 | 40 | 3 | 44 | 3 | 5 |
| Received at least 1 dose of study drug | 37 | 72 | 40 | 3 | 44 | 3 | 5 |
| Completed | 34 | 67 | 34 | 3 | 40 | 2 | 5 |
| Not completed | 3 | 5 | 6 | 0 | 4 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 3 | 0 | 4 | 0 | 0 |
Biomarker response was defined as a \> 20% decrease in the biomarker AFP from baseline during 8 weeks of treatment. Data presented is median overall survival of those participants who achieved the defined biomarker response. Participants enrolled in Part A had a baseline AFP level of \>1.5 upper limit normal (ULN). Participants enrolled in Part B had baseline AFP level \<1.5 ULN.
| Months | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B LY2157299 | Part C LY2157299 |
|---|---|---|---|---|
| Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS) | 19.0 (1.5 to 25.1) | 21.5 (2.9 to 34.2) | 24.2 (3.0 to NA) | 17.9 (12.6 to 32.8) |
Biomarker response was defined as a \> 20% decrease in the biomarker TGF-B from baseline. Data presented is median overall survival of those participants who achieved biomarker response.
| Months | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B LY2157299 | Part C LY2157299 |
|---|---|---|---|---|
| Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS) | 11.9 (5.4 to 15.6) | 10.1 (4.9 to 15.5) | 21.9 (12.4 to NA) | 22.88 (16.2 to 31.8) |
TTP is measured from the date of first dose to the first date of progression of disease based on the investigator review of tumor response using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
| Weeks | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib |
|---|---|---|---|---|---|
| Time to Progression (TTP) | 12.1 (6.3 to 17.6) | 7.1 (6.3 to 12.7) | 18.0 (10.0 to 24.0) | 36.0 (18.0 to 36.0) | 17.9 (12.1 to 24.0) |
Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.
| Liter per hour (L/hr) | LY2157299 |
|---|---|
| Population Pharmacokinetics (PK) Mean Population Clearance of Galunisertib | 33.6 ± 48 |
| milligrams (mg) | LY2157299 |
|---|---|
| Recommended Dose for Phase 3 Hepatocellular Carcinoma (HCC) Trials | 300 |
OS duration is measured from the date of first dose to the date of death from any cause.
| Weeks | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib |
|---|---|---|---|---|---|
| Overall Survival (OS) | 39.1 (24.1 to 52.6) | 29.6 (19.6 to 38.6) | 73.0 (45.4 to 104.7) | 30.3 (28.4 to 70.3) | 89.6 (70.3 to 104.9) |
PFS duration is measure from the date of first dose to the first date of objective progression of disease or death from any cause. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
| Weeks | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 12 (6.3 to 12.6) | 6.6 (6.1 to 10.9) | 13.4 (7.4 to 23.3) | 28.4 (6.0 to 36.0) | 28.4 (17.4 to 45.3) |
The percentage of participants who achieved best overall response of either Complete Response (CR) or Partial Response (PR). The overall response rate for each dose with be estimated by dividing the number of confirmed responders by the number of participants who received at least one dose of study drug. Per RECIST v.1.0 criteria CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib |
|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 3.7 | 0 | 2.3 |
DoR is measured from the date of the first objective status assessment of a Complete Response (CR) or Partial Response (PR), as determined by RECIST v1.1, to the first date of objective progression of disease or death from any cause. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 millimeter (mm). Tumor-marker results must have normalized. PR is defined as at least 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
| Weeks | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib |
|---|---|---|---|---|---|
| Duration of Tumor Response (DoR) | — | — | 37.6 (25.1 to 50.1) | — | 40.2 (12.1 to 84.1) |
TTF is measured from the date of first dose until the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause.
| Weeks | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib |
|---|---|---|---|---|---|
| Time to Treatment Failure (TTF) | 13.4 (8.6 to 18.0) | 9.9 (8.1 to 12.1) | 19.3 (12.1 to 26.3) | 26.3 (19.3 to 54.0) | 49.3 (18.3 to 75.3) |
FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72; FACT-Hep score range 1-180, and Trial-Outcome Index (TOI) score range 1-128, to assess health related quality of life in participants with cancer. Higher scores reflect a better health state.
| units on a scale | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib |
|---|---|---|---|---|---|
| PWB | 0.06 ± 3.6 | -0.16 ± 5.0 | 0.04 ± 3.4 | -1.67 ± 1.5 | -1.75 ± 4.4 |
| SWB | 0.96 ± 2.9 | 0.24 ± 3.4 | 0.37 ± 4.5 | -1.11 ± 2.8 | 0.41 ± 3.6 |
| EWB | 0.55 ± 2.7 | 1.17 ± 3.9 | 1.13 ± 4.1 | 2.87 ± 2.8 | 0.85 ± 2.5 |
| FWB | -0.02 ± 5.3 | 0.84 ± 3.6 | 1.20 ± 4.7 | -1.00 ± 1.0 | -1.19 ± 4.6 |
| HCS | 1.93 ± 7.6 | 1.40 ± 7.8 | 0.89 ± 6.8 | 1.08 ± 6.0 | -3.79 ± 7.3 |
| FACT-Hep | 2.04 ± 1.53 | 1.50 ± 17.5 | 0.58 ± 18.2 | -0.50 ± 6.5 | -8.54 ± 17.0 |
| TOI | 1.34 ± 13.3 | 1.14 ± 14.6 | 1.17 ± 12.2 | -1.92 ± 7.7 | -8.28 ± 13.7 |
Time to worsening of symptoms used minimally important differences to evaluate Physical Well Being (PWB), Functional Well Being (FWB), Hepatocellular Cancer Symptoms (HCS), National Comprehensive Cancer Network (NCCN)/FACT Hepatocellular Symptoms (FHS), Trial-Outcome Index (TOI). PWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; FWB time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; HCS time to worsening was defined as participants who had change in a subscale of ≥ 5 point decrease from baseline; FHS time to worsening was defined as participants who had change in a subscale of ≥ 2 point decrease from baseline; TOI time to Worsening was defined as participants who had change in the subscale of ≥ 7 point decrease from baseline.
| Days | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 2 - 300mg LY2157299 |
|---|---|---|---|---|
| PWB | 114.0 (30.0 to NA) | 113.0 (57.0 to NA) | 113.0 (58.0 to 170.0) | 30.0 (29.0 to 57.0) |
| FWB | 57.0 (30.0 to 86.0) | 88.0 (57.0 to 371.0) | 64.0 (30.0 to 172.0) | 30.0 (29.0 to 58.0) |
| HCS | 114.0 (57.0 to NA) | 113.0 (85.0 to NA) | 170.0 (57.0 to 567.0) | 31.0 (29.0 to 57.0) |
| FHS | 55.0 (29.0 to 86.0) | 57.0 (30.0 to 113.0) | 57.0 (30.0 to 113.0) | 30.0 (29.0 to 30.0) |
| TOI | 114.0 (57.0 to NA) | 113.0 (58.0 to 371.0) | 179.0 (57.0 to 567.0) | 30.0 (29.0 to 31.0) |
Collected over Baseline up to 41.5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Cohort 1 - 160 mg LY2157299 | 33/37 (89.2%) | 15/37 (40.5%) | 32/37 (86.5%) |
| Part A Cohort 2 - 300 mg LY2157299 | 63/72 (87.5%) | 36/72 (50%) | 64/72 (88.9%) |
| Part B - 300 mg LY2157299 | 26/40 (65%) | 16/40 (40%) | 38/40 (95%) |
| Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | 36/44 (81.8%) | 28/44 (63.6%) | 44/44 (100%) |
| Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab | 5/5 (100%) | 2/5 (40%) | 5/5 (100%) |
| Event | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab |
|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/37 | 7/72 | 3/40 | 1/3 | 6/44 | 0/3 | 0/5 |
| Duodenal ulcerGastrointestinal disorders | 0/37 | 0/72 | 0/40 | 1/3 | 0/44 | 0/3 | 0/5 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/37 | 1/72 | 1/40 | 1/3 | 0/44 | 0/3 | 1/5 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/37 | 1/72 | 2/40 | 1/3 | 1/44 | 0/3 | 0/5 |
| General physical health deteriorationGeneral disorders | 0/37 | 0/72 | 0/40 | 1/3 | 0/44 | 0/3 | 0/5 |
| Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/37 | 0/72 | 0/40 | 1/3 | 0/44 | 0/3 | 0/5 |
| Embolic strokeNervous system disorders | 0/37 | 0/72 | 0/40 | 0/3 | 0/44 | 1/3 | 0/5 |
| Renal injuryRenal and urinary disorders | 0/37 | 0/72 | 0/40 | 1/3 | 0/44 | 0/3 | 0/5 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/37 | 0/72 | 2/40 | 1/3 | 1/44 | 0/3 | 0/5 |
| Acute hepatic failureHepatobiliary disorders | 0/37 | 0/72 | 0/40 | 0/3 | 0/44 | 0/3 | 1/5 |
| Event | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab |
|---|---|---|---|---|---|---|---|
| Weight decreasedInvestigations | 4/37 | 8/72 | 10/40 | 3/3 | 24/44 | 0/3 | 0/5 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/37 | 2/72 | 3/40 | 0/3 | 4/44 | 3/3 | 1/5 |
| FlatulenceGastrointestinal disorders | 2/37 | 0/72 | 1/40 | 2/3 | 3/44 | 0/3 | 0/5 |
| FatigueGeneral disorders | 9/37 | 14/72 | 14/40 | 2/3 | 11/44 | 0/3 | 2/5 |
| Decreased appetiteMetabolism and nutrition disorders | 6/37 | 7/72 | 7/40 | 2/3 | 10/44 | 0/3 | 0/5 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/37 | 2/72 | 1/40 | 0/3 | 1/44 | 2/3 | 0/5 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/37 | 1/72 | 1/40 | 1/3 | 28/44 | 0/3 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 5/37 | 10/72 | 11/40 | 1/3 | 21/44 | 1/3 | 1/5 |
| Abdominal distensionGastrointestinal disorders | 2/37 | 2/72 | 5/40 | 0/3 | 4/44 | 1/3 | 2/5 |
| Abdominal painGastrointestinal disorders | 7/37 | 11/72 | 8/40 | 1/3 | 7/44 | 0/3 | 2/5 |
All enrolled participants.
| Age, Continuous(years) | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 63.4 ± 10.8 | 63.3 ± 10.8 | 68.1 ± 9.6 | 70.3 ± 4.7 | 63.7 ± 9.8 | 54.0 ± 11.3 | 63.2 ± 11.2 | 64.3 ± 10.5 |
| Sex: Female, Male(Participants) | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 5 | 13 | 4 | 0 | 5 | 0 | 0 | 27 |
| Male | 32 | 59 | 36 | 3 | 39 | 3 | 5 | 177 |
| Race (NIH/OMB)(Participants) | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 1 | 7 | 1 | 0 | 6 | 2 | 4 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 0 | 7 | 0 | 0 | 9 |
| Black or African American | 2 | 3 | 1 | 0 | 2 | 0 | 1 | 9 |
| White | 34 | 58 | 35 | 2 | 20 | 0 | 0 | 149 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 3 | 0 | 9 | 1 | 0 | 15 |
| Region of Enrollment(Participants) | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab | Total |
|---|---|---|---|---|---|---|---|---|
| New Zealand | 2 | 5 | 4 | 0 | 12 | 0 | 0 | 23 |
| United States | 6 | 12 | 4 | 1 | 10 | 3 | 5 | 41 |
| Italy | 12 | 15 | 9 | 0 | 4 | 0 | 0 | 40 |
| Australia | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 5 |
| France | 12 | 27 | 16 | 0 | 14 | 0 | 0 | 69 |
| Germany | 4 | 7 | 4 | 2 | 4 | 0 | 0 | 21 |
| Spain | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 5 |
| Alpha-Fetoprotein(Participants) | Part A Cohort 1 - 160 mg LY2157299 | Part A Cohort 2 - 300 mg LY2157299 | Part B - 300 mg LY2157299 | Part C Cohort 1 - 160 mg LY2157299 + Sorafenib | Part C Cohort 2 - 300 mg LY2157299 + Sorafenib | Part D Cohort 1 - 160 mg LY2157299 + Ramucirumab | Part D Cohort 2 - 300 mg LY2157299 + Ramucirumab | Total |
|---|---|---|---|---|---|---|---|---|
| < 200 nanograms per Liter (µg/L) | 9 | 23 | 28 | 2 | 20 | 1 | 2 | 85 |
| 200 - 400 (µg/L) | 3 | 5 | 0 | 0 | 4 | 0 | 0 | 12 |
| > 400 (µg/L) | 23 | 43 | 0 | 1 | 16 | 2 | 2 | 87 |
| Unknown/Not reported | 2 | 1 | 12 | 0 | 4 | 0 | 1 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2011 to primary completion in Jun 2019, 98 months.
Results were first posted in Aug 2020, 1 year 2 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 98 months is above that.
Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY-2157299